Outcome Resources Inc.

1-866-877-2053

Pharmacy Benefits Management

 

The Hospice Clinician Blog

Subscribe to Blog:

Search:



ABH Gel  Abilify  ACA  Acetaminophen  acetaminophen  acid suppression. ranitidine  aclidinium bromide  acute dystonia  acute phosphate nephropathy  Adult Failure to Thrive  Advair  Advance Care Planning  adverse drug events  Affordable Care Act  Agitation  agitation  akathisia  Akorn  albuterol  aliskiren  Allergan  allergy  alprazolam  Alzheimer's  Alzheimers  Ambien  Amitiza  and Jardiance (empagliflozin)  and Methadone (Dolophine)  Angina  anorexia  Anoro Ellipta  anoro ellipta  antibiotics  Anticholinergics  anticoagulants  anticoagulation  Antidepressant  antidepressant  antidepressants  antiplatelet  antipsychotic  antipsychotics  anxiety  appetite  appetite stimulant  Arcapta Neohaler  Aricept  arrhythmia  aspirin  asthma  Ativan  atropine  Avastin  Avinza  Azithromycin  azithromycin  Baclofen  baclofen  barbiturates  Basaglar  Beers Criteria  Beers List  Belsomra  Benzodiazepines  benzodiazepines  Beta‐2 Agonists  Bevespi Aerosphere  bexarotene  bleeding  bone metastases  bone pain  Boniva  bowel movement  breakthrough pain  Breo Ellipta  breo ellipta  Brillinta  Brintellix  brintellix  brochodilator  bronchodilator  Buprenorphine  BuprenorphinePranay Parihar  cancer pain  carbidopa-levodopa  Cardiac Arrhythmia  cardiovascular  Celebrex  Celexa  chlorpromazine  Chlorpromazine (Thorazine)  cholesterol  cholinesterase inhibitors  Choosing Wisely  Cimetidine  CitAD  Citalopram  citalopram  Citalopram (Celexa)  clinical services  clotting  CMS  codeine  colace  Combivent  Combivent Respimat  Comfort Kit  Compazine  compliance  compounded medication  Compro  Comtan  conference  constipation  contact hours  continuing education  controlled drugs  controlled prescriptions  controlled substance  COPD  Coronary Artery Disease  corticosteroid  Coumadin  counterfeit drugs  CR 8358  Crestor  dabigatran  dabigatran etexilate  Dame Cicely Saunders  Darvocet  Darvon  DEA  Debility  decadron  Delirium  delirium  dementia  depression  desvenlafaxine  dexamethasone  Dexilant  diabetes  Diazepam  discontinuation letter  discontinuation of medication  docusate  Dopamine Antagonist  Dopamine Antagonist Antiemetics  Doxepin  drug disposal  drug diversion  drug shortage  drug shortages  dry powder inhaler  Duloxetine  DuoDerm  dyskinesia  dyspnea  E-Kit  Edluar  Education  Eliquis  Endo  Endocet  Endodan  enema  Entacapone  escitalopram  Escitalopram (Lexapro)  esophagitis  eszopiclone  ethics  Evzio  Exalgo  Exelon  famotidine  Farxiga (dapagliflozin)  faxing prescriptions  FDA  FDA REMS  fenofibrate  fentanyl  fentanyl sublingual spray  fetzima  first-generation antihistamines  fixed dose combination  fleet enema  flu vaccine  fluoroquinolone  fungal infection  Gabapentin  Gastroesophageal reflux disease  Gastrointestinal  generic  generic drug  generic Lexapro  generic medication  generic Seroquel  generic substitution  generics  GERD  Glycopyrrolate  H2 Blockers  H2RA  Haldol  haldol  Haloperidol  haloperidol  Haloperidol (Haldol)  Heart  Heart Failure  HELP Hospice Act  hiccups  HIS  honey  hospice  Hospice Action Network  hospice advocacy  hospice ceu  hospice clinical  hospice clinical support  Hospice Compliance  hospice compliance  hospice Conditions of Participation  hospice conference  hospice constipation  hospice COP  hospice CoP compliance  hospice cough  Hospice Diagnosis  hospice docusate  hospice drug  hospice drug choice  hospice drug disposal  hospice drug dosage  Hospice Drugs  hospice drugs  hospice drugs,delirium,haloperidol,haldol,antipsychotics  hospice education  hospice education programs  Hospice Item Set  hospice medication  Hospice Medication Chart  hospice medication disposal  hospice medication orders  hospice medication review  hospice medication reviews  Hospice Medications  hospice medications  hospice methadone  hospice opioid  hospice opioid conversion  hospice opioids  hospice pain management  hospice patient  hospice patient care  hospice patient discharge  hospice payment reform  hospice PBM  hospice pbm  hospice PBM choice  hospice pharmacist  hospice pharmacy  hospice pharmacy benefit manager  hospice pharmacy claim reporting  hospice pharmacy decision  Hospice Pharmacy Solutions  hospice seizure  hospice symptom management  Hospice UK  hospira carpuject  hycodan  Hydrochlorothiazide  Hydrocodone  hydrocodone  hydrocodone/APAP  hydrocodone/APAP recall  hydromorphone  hydromorphone recall  Hyoscyamine  hypnotic  hypoglycemics  Hysingla ER  IBS  idarucizumab  incomplete cross-tolerance  infection  influenza  Inhaled Corticosteroids  inhaler  inhaler technique  INR  Insomnia  insomnia  insulin  Intermezzo  Invokana (canagliflozin)  ipratropium  irritable bowel  Januvia  Kadian  Kaleo  ketamine  Ketoacidosis  Ketoconazole  kidney disease  Lantus  laxative  Lazanda  leg cramps  leukotriene-receptor antagonist  Levsin  Linaclotide  lioresal  Lipitor  long acting opioids  Lorazepam  Lortab  lortab  lovastatin drug interactions  low dose aspirin  LTRA  Lubiprostone  Lundbeck and Takeda  Lunesta  lung cancer  Lyrica  medical honey  medical marijuana  Medicare  Medicare Hospice Benefit  Medicare Part D  medication adherence  medication allergy  medication disposal  medication errors  medication orders  medication recall  medication review  medication shortage  medication tapering  Medihoney  Megace  Meningitis  meperidine  metered dose inhaler  Methadone  methadone dosage  Methylprednisolone  methyphenidate  Metoclopramide  metoclorpramide  Midazolam  morphine  morphine injection recall  morphine sulfate  Movantik  multiple sclerosis  muscle relaxants  Naloxone HCl injection  Namenda  naproxen  narcotic  National Prescription Take Back Initiative  Nausea  nausea  NDC  nebulized opioid  Nexium  NHPCO  niacin  Nitrate  nitrofurantoin  Nitroglycerin  Nizoral  non-specific hospice diagnoses  norco  NSAID  OIG  olanzapine  Olodaterol  omeprazole  ondansetron hydrochloride  Opana  Opana ER  Opioid  opioid  opioid allergy  opioid disposal  opioid induced constipation  Opioid Overdose  opioid-induced constipation  opioids  oral anticoagulants  Outcome Resources  overactive bladder  Oxybutynin  Oxycodone  oxycodone  oxycodone/APAP  Oxycontin  oxycontin  oxymorphone  oxytrol  palliative care  parenteral opioid  Parkinson's  Parkinson's Disease  Part D  Part D Prior Authorization  pathway to sucess webinar  Pathways to Success  Pathways to Success Conference  patient compliance  PBM decision  pediatric  pediatric end of life care  pediatric hospice  pediatric hospice care  pediatric palliative  pediatric palliative care  pediatric palliative symptom management  Pepcid  peptic ulcer disease  Percocet  Percodan  Personalize Your Care Act  Phenadoz  Phenergan  PPI  PPIs  Pradaxa  Praxbind  pressure ulcers  pressurized metered dose inhaler  Prochlorperazine  Product Information  Promethazine  Promethegan  Propoxyphene  Prostate Cancer  Proton Pump Inhibitor  Proton Pump Inhibitors  pruritis  pseudo-parkinsonism  psychotropic  PUD  QT interval  QT Prolongation  quetiapine  quinine  Recall  Refresh  Reglan  reglan  Relistor  REMS  renal impairment  research  resperidone  Respimat  respiratory medications  Restoril  Revatio  Risperidone  risperidone  Robinul  Roflumilast  Ropinirole  Rytary  safety alert  Salonpas  Sativex  Savaysa  Schedule II  schedule II  schedule II medications  scheduled medications  Scopolamine  secretions  Selective Serotonin Reuptake Inhibitor  sennosides  Seroquel  Seroquel XR  Sesi-Care  SGLT2 inhibitors  Silenor  Singulair  Skilled Nursing Facility  skilled nursing facility  Sleep  SNF  soft mist inhaler  Sonata  Spiriva  Spiriva Respimat  Sprix  SSRI  Stalevo  START and STOPP  Statin  statin  statins liver function  statins safety  statins side effects  Steroid  Stiolto Respimat  stool softener  Striverdi  Striverdi Respimat  stroke  Sublingual Nitroglycerin  subsys  sulfa allergy  Suvorexant  Symbicort  Tagamet  Targretin  targretin  TdP  Temazepam  tertiary TCAs  thorazine  Tiotropium  tiotropium  TIRF REMS Access Program  topical metronidazole  Transderm Scop  transmucosal immediate-release fentanyl  trazadone  Trintellix  Tudorza Pressair  tussionex  Tylenol  tylenol  ulcer  United Kingdom  Utibron Neohaler  Valium  Versed  Vicodin  vicodin  vicoprofen  viibryd  vilazodone  vitamin K  vomiting  vortioxetine  warfarin  Wound Care  wound care  writing orders  Xarelto  zaleplon  Zantac  zithromax  Zocor  Zofran  zogenix  zohydro  Zolpidem  zolpidem  Zolpimist  Zydone  zyhydro  Zyprexa 

07/01/2016

FDA approves a brand name change for antidepressant, Brintellix to Trintellix

Jenny Chau, RDH, PharmD

Brintellix (vortioxetine) is a relatively new serotonergic antidepressant, approved to treat major depressive disorder in March 2014, as described in our previous blog. In recent FDA MedWatch news, there were numerous reports of name confusion between Brintellix and the antiplatelet drug, Brillinta, not only among the consumers, but also among healthcare professionals. On May 2, 2016, the FDA approved a brand name change from Brintellix to Trintellix in order to decrease the risk of prescribing and dispensing errors. As of June 2016, Brintellix will be marketed as Trintellix and will also have a new National Drug Code (NDC).

Although there is a new brand name and NDC, the formulation, indication and dosages of 5 mg, 10 mg and 20 mg tablets will remain the same. Pharmacies, insurance carriers and healthcare providers are advised to update their medication-related electronic systems with the new brand name. During the transition to the new brand name, healthcare providers are also advised to carefully check to make sure they have prescribed or dispensed the correct medication and educate patients about the name change.

The FDA also encourages patients and healthcare professionals to report medication errors, name confusion, adverse events or side effects related to the use of vortioxetine (Brintellix/Trintellix) and Brillinta by calling FDA’s MedWatch Program at 800-332-1088 or visit http://www.fda.gov/Saftety/MedWatch.

Reference:

FDA Drug Safety Communication: FDA approves brand name change for antidepressant drug Brintellix (vortioxetine) to avoid confusion with antiplatelet drug Brillinta (ticagrelor). (2016, May 2). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm497942.htm.




06/21/2016

No Cardiovascular Benefit on Niacin, Fenofibrate Combinations with Statins

Jennifer Chen, PharmD, CGP

The FDA has withdrawn approvals for the use of niacin or fenofibrate in combination with statins for the treatment of high cholesterol. The FDA also withdrew approval of the indications related to the adjunctive therapy to a statin with niacin extended-release tablets (Niaspan) or fenofibrate delayed-release capsules (Trilipix). This decision directly impacts two medications, Advicor and Simcor, both contain niacin with a statin (lovastatin and simvastatin, respectively) and they are no longer on the market.

The FDA made this decision based on several large trials including AIM-HIGH, ACCORD and HPS2-THRIVE, which collectively showed no benefits of adjunctive therapy to statins for the reduction in the risk of cardiovascular events. According to the studies, further reduction of LDL cholesterol did not translate to the reduction of cardiovascular events. In the absence of benefits, serious adverse events such as myopathy were statistically significantly higher in patients taking niacin with statin.

Niacin and fenofibrate are still available individually on the market. While niacin is also available over-the-counter, patients medications should be reviewed and patients should be educated on efficacy concerns about combination therapy as the benefits of the drugs no longer outweigh the risks.

Preventive care, referring to medical interventions with anticipated long-term benefits, is often inappropriately continued near the end of life. Majority of patients, who were on cholesterol-lowering medications prior to starting hospice, remained on the therapy. This is a great opportunity for hospice care providers and patients to discuss the appropriateness of continuing preventive care as part of an important conversation about prognosis. As patients are often worried about the risks associated with discontinuation, recent studies have shown that the discontinuation of statin therapy in the setting of advanced illness is actually safe and may be associated with benefits. These benefits include improved quality of life, reduced pill burden and reduction in medication costs.

Our pharmacists have put together a patient directed letter to help you communicate with your patients regarding the discontinuation of cholesterol-lowering drugs. This letter can be found in the clinical resources section of member section.




06/10/2016

Hospice Pharmacy Solutions and Outcome Resources Clinical Support Services

Jenny Chau, RDH, PharmD

Hospice Pharmacy Solutions (HPS) and Outcome Resources (OR) have dedicated clinical pharmacists, who work with our hospice providers, to provide quality care to the hospice patients we serve.  Many of the clinicians at the hospices we work with may not be aware that our clinical pharmacists provide a wide range of clinical support services and are available 24/7. This article will focus on some of the core, highly rated services that are valued by hospice providers.  These clinical support services include: pharmacist medication reviews, pharmacists consultations, newsletters and blog articles, educational presentations and online clinical resources.

Pharmacist Medication Reviews

Comprehensive medication reviews provided by our clinical pharmacists exceed the standards of the Medicare Conditions of Participation (CoP). The medication review service helps many hospice providers to stay in compliance from patient being admitted to discharge. Medications were reviewed not only at admission, but also re-reviewed in accordance to each hospice interdisciplinary team (IDT) meetings depending on the hospices’ need. In each medication review, our clinical pharmacists make recommendations on coverage decisions, highlight any cost-effective therapeutic alternatives, identify clinically significant drug interactions, and point out any therapeutic duplications to help decrease cost and adverse effects. At the end of each medication review, a personalized summary of recommended action items is provided to help with disease and symptoms management. Our medication reviews are unique and highly rated for providing clear and concise recommendations for the Interdisciplinary Team (IDT) to help improve quality of patient care, reduce medication cost and stay compliance with CoP.

Pharmacist Consultations

Pharmacist consultations are available 24/7 every day in the year. This is a great opportunity for nurses, physicians and pharmacists to collaborate and provide the best possible care to your patients. Our clinical pharmacists are here to help discuss any medication and/or symptom related topics relating to your patients. Common topics include: opioid dose conversion, pain and palliative symptom management, and general drug information (i.e. availability/formulation, therapeutic alternatives, cost and adverse effects).

Newsletters and Clinical Blogs

Our newsletter, The Clinician, and our clinical blog contain original hospice oriented articles that are prepared and chosen carefully by our clinical team. The Clinician is our quarterly newsletter that focuses on hospice pharmacy, drugs and guidelines updates. Some of the hot topics in our newsletters include Opioid Infusions in Hospice Patients, COPD and Inhaled Corticosteroids, and Diabetes Management Decisions in Hospice. There are over 10 years of past issues of The Clinician archived on our web-site for easy access. Our clinical blog articles are posted more frequently on our website to address timely clinical issues to help you stay current on drug information and other hospice related topics.

Educational Presentations

We provide three different types of educational presentations: a monthly webinar series called Pathways to Success, customized live in-service presentations tailored to the clients’ needs, and pre-recorded self-paced educational presentations. We are accredited by the California Board of Registered Nurses to offer nursing continued education (CE) credits and all of these presentations are available for nursing CE.  Pathways To Success Live Webinar Series is our monthly continuing educational series provided via web-based interactive presentations. The webinars feature guest speakers or HPS/OR clinical pharmacists on various hospice related topics such as Referral Inquiry to Admission: Growing Your Census, Management of Delirium in the Hospice Patient, and many more. In addition, our clinical pharmacists also design and provide clinical education on topics that our hospice partners are interested in and provide live in-service presentations. Some of the very population educational presentations were recorded and made available as self-pace webinar courses, which our hospice partners can register online and complete at your own convenience.

Clinical Resources

Our exclusive member login website contains an extensive selection of various clinical resources, charts, protocols, clinical algorithm and pathways, and other tools to assist hospice clinicians in many areas of practice. These are printable documents that hospice providers can keep in their pockets for convenient access. A few examples of our clinical algorithms include: Nausea and Vomiting Management, Anxiety and Agitation Management, and Hallucination Management. Another very popular clinical chart is our Inhaled Respiratory Medications Chart, which help clinicians easily identify and avoid therapeutic duplication in respiratory medications.

In addition, we understand that drug discontinuation at end of life may be difficult for patients and families to understand. We have developed handouts on specific drugs recommended for discontinuation in hospice patients. These are written specifically towards patients and family members and nurses have found them helpful as a communication tool. Examples of the handouts include: Discontinuation of Anticoagulants, Cholesterol Lowering Drugs, and Cognitive Enhancement Drugs in end stage dementia.

Hospice Pharmacy Solutions and Outcome Resources provide you with pharmacy clinical support 24/7, 365 days a year with one goal in mind, which is to help you succeed as a hospice provider. Talk to one of our HPS or Outcome Resources representatives to learn more about our clinical services. For more information on our exclusive member login, please visit https://members.outcomeresources.com/memberlogin.asp or contact your Account Manager. We look forward to our future collaboration!




06/02/2016

Medication Safety Alert: Fluoroquinolone Antibiotic Risks

Jim Joyner, PharmD, CGP

The US Food and Drug Administration has issued new labelling requirements for all fluoroquinolone antibiotics due to serious risks for disabling and potentially permanent adverse effects. The new labelling will state that these antibiotics should not be used in patients with uncomplicated infections because the risks generally will outweigh the benefits. FDA mentions these specific infections as examples where Fluoroquinolone risks outweigh the benefits:  sinusitis, bronchitis, and uncomplicated urinary tract infections.

Fluoroquinolone antibiotics for systemic use (i.e. tablets, capsules, and injections):

Moxifloxacin (Avelox)                            Ciprofloxacin (Cipro)

Gemifoxlacin (Factive)                          Levofloxacin (Levaquin)

Ofloxacin (available as generic only)

The serious risks cited by the FDA include:  tendon rupture, peripheral neuropathy, QT prolongation with torsades de pointes, phototoxicity, central nervous system effects, and exacerbation of myasthenia gravis. 

Fluoroquinolones have been known to have the potential for serious adverse effects for a long time prior to this latest move by the FDA.  In 2008, the FDA required these antibiotics to contain a black-box warning because they increase the risk of tendonitis and tendon rupture by three to four-fold.   Other serious reactions reported are: retinal detachment, hallucinations, psychotic reactions, acute kidney failure, depression, painful rashes, and hearing problems.

A 2001 study by Dr. Jay Cohen (1) documented the following fluoroquinolone adverse reaction rates:

a) Nervous system symptoms occurred in 91% of patients (pain, numbness, dizziness, weakness, anxiety, psychosis, and memory loss).

b) Musculoskeletal symptoms in 73% of patients (tendon ruptures, tendonitis, joint swelling)

c) Sensory symptoms in 42% of patients (tinnitus, altered vision, olfactory and auditory disturbance)

d) Cardiovascular symptoms in 36% of patients (tachycardia, shortness of breath, chest pain, palpitations)

Due to the serious risks for major debilitating adverse effects, fluoroquinolone antibiotics should only be deployed in serious infections where other options are not available.   It is uncommon that a fluoroquinolone would be the only antibiotic that could be used.

 

Reference

1. Cohen JS. Peripheral Neuropathy with Fluoroquinolone Antibiotics. Annals of Pharmacotherapy 2001, Dec;35(12):1540 47.




05/26/2016

Fixed-dose combination therapy for COPD – Why one size does not fit all?

Jennifer Chen, PharmD, CGP

Fixed-dose combination therapy offers convenient dosing and improves compliance; however, their place in hospice therapy is limited and these novel inhalers are expensive. This article will discuss new fixed-dose combination therapies, their limitation and the cost-effective alternative for hospice patients.

LAMA/LABA combination

Inhaled bronchodilators are the cornerstone of treatment in COPD. Both long-acting muscarinic antagonists (LAMAs) and long- acting beta 2-adrenergic agonists (LABAs) are used as long-term maintenance treatment of airflow obstruction in patients with COPD. The fixed-dose combination inhalers are designed to provide extra bronchodilation compared with either therapy alone. Currently, Anoro Ellipta (umeclidinium-vilanterol) and Stiolto Respimat (tiotropium-olodaterol) are the only FDA approved LAMA/LABA combinations available on the market that may be given in a convenient once daily dosing.

Two new LAMA/LABA combination inhalers received FDA approvals but not yet available on the market. Utibron Neohaler (glycopyrrolate-indacaterol) and Bevespi Aerosphere (glycopyrrolate-formoterol), approved in Oct 2015 and April 2016, respectively, offer another option of LAMA/LABA dual combination bronchodilator to patients with COPD. Both inhalers contain the same long-acting muscarinic antagonist, glycopyrrolate, with the different LABAs (indicaterol versus formoterol). Both of these new inhalers are given twice daily.

One of the notable differences between all of these products is the type of inhalation device used. Anoro Ellipta and Utibron Neohaler deliver medication via a dry powder inhaler whereas Stiolto Respimat and Bevespi Aerosphere use a metered-dose inhaler. Both of these devices are breath-actuated, that is, requiring effective positive respiratory effort to inhale medication.

ICS/LABA combination

Inhaled corticosteroid (ICS) therapy is recommended as combination treatment with LABA for patients with a history of frequent acute exacerbations of their COPD. Breo Ellipta, approved in April 2015, combines the new LABA vilanterol with an inhaled corticosteroid already on the market, fluticasone. Vilanterol allows this product to be dosed once daily compared with existing ICS/LABA combination products that are dosed twice daily including Advair Diskus (fluticasone-salmeterol), Symbicort (budesonide-formoterol) and Dulera (mometasone-formoterol).

Long-term ICS treatment is associated with multiple adverse effects including fractures, oral fungal overgrowth and respiratory infections. Therefore, treatment with ICS in patients with COPD should be carefully evaluated when assessing the risk/benefit ratio due to the risk of pneumonia. Their benefit in patients at low risk of exacerbations is questionable1.

Place in hospice therapy

The major disadvantage of these combination therapies for the hospice patient is the method in which the medication is delivered via a metered-dose inhaler or a dry powder inhaler. In patients with advanced disease, who may not have enough positive inhalation, nebulized therapies may be more efficacious than inhalers. Therefore, the combination treatment of short-acting muscarinic antagonist (SAMAs) and short-acting beta 2- adrenergic agonist (SABAs), such as DuoNeb (ipratropium-albuterol) is usually recommended as an alternative. Routine use of DuoNeb should provide an equivalent coverage compared to LAMA/LABA combination products. Although the dosing frequency (four times daily) may be considered as a drawback compared to the long-acting combination products, the short-acting combination therapy may also be used on as-needed basis for acute management of dyspnea in addition to the scheduled dosing. Since the newer combination products are generally cost prohibitive, DuoNeb also serves a cost-effective alternative for hospice patients. In cases where a patient has high risk of exacerbation, a low dose oral corticosteroid may be considered and they are inexpensive compared to inhaled corticosteroids. 

View a comparison chart of fixed-dose combination inhalers and cost-effective alternative.

A complete chart on inhaled respiratory medications with dosing information and pricing can be found in the Clinical Resources in our member section.

 

Reference

Magnussen, Disse, Rodriguea-Roisin, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014;371:1285-4. 




05/02/2016

Utilization of Haloperidol in the Skilled Nursing Facility for Symptom Management at End of Life

Jim Joyner, Pharm.D., C.G.P.

CMS has established very restrictive regulatory criteria for the use of Haloperidol and other psychotropic drugs for patients who reside in the SNFs. These criteria include restrictions on indications for use, duration of therapy, daily dose limits, monitoring, and more. The information is spelled out in F-329 Unnecessary Drugs (CMS Skilled Nursing Facility Regulations). The regulations are intended for nursing home patients who are NOT being treated under “end of life care” and this is clearly spelled out in F-329.

F-329 Unnecessary Drugs contains specific language that provides an exception to the specific criteria for antipsychotic drug use (including Haloperidol) for hospice patients in the SNF. Subsection 483.25 (l) in this F-tag contains an extensive table (Table 1) which lists examples of numerous medications for which CMS is concerned about, including all antipsychotic drugs. At the end of this extensive table is a section titled, simply, “Exception”. Here is the exact language:

 

Exception: When antipsychotic medications are used for behavioral disturbances related to Tourette’s disorder, or for non-psychiatric indications such as movement disorders associated with Huntington’s disease, hiccups, nausea and vomiting associated with cancer or chemotherapy, or adjunctive therapy at end of life.

 

This means that when Haloperidol (or any antipsychotic drug) is being used for managing symptoms at end-of-life in the SNF, the regulatory criteria on max dosage, duration of therapy or related issues do not apply. Haloperidol is used extensively in hospice and palliative care for management of terminal delirium, severe agitation of end-stage dementia, and for management of nausea – vomiting. It is highly effective for these indications and generally well tolerated in many hospice patients, however in many cases, doses greater than 2 mg per day are required and are clinically appropriate. Haloperidol is recommended as a drug of choice for terminal delirium by several well respected palliative care experts and organizations (references available upon request if you need them).

Make sure that the patient’s health record clearly indicates that the patient is under hospice for ‘end of life’ care.




03/24/2016

Diabetic Medications Updates

Jennifer Chen, PharmD, CGP

SGLT2 inhibitors

Last year, the FDA released a drug safety communication, which cautioned the use of SGLT2 inhibitors, due to case reports of ketoacidosis in patients who were being treated with these medications. Recently, the FDA has updated the labels for SGLT2 inhibitors to include the risks for both ketoacidosis and serious urinary tract infections. Patients in these case reports were found to start with urinary tract infection, which then progressed to potentially fatal urosepsis and pyelonephritis that required hospitalization or dialysis to treat kidney failure. Patients who continue to take these medications should be taught to recognize the symptoms of ketoacidosis, which include nausea, vomiting, abdominal pain, fatigue and difficulty breathing. Ketoacidosis can occur even if their blood glucose is not excessively high. Patients with suspected ketoacidosis should stop taking the SGLT2 inhibitor and receive treatment promptly. Clinicians are encouraged to report any side effects to the FDA MedWatch program. 

 

SGLT2 inhibitor is a class of diabetic medication that works by stopping glucose from being reabsorbed into the blood. Medications in this class include Invokana (canagliflozin), Farxiga (dapagliflozin), and Jardiance (empagliflozin).

 

Rosiglitazone

The FDA imposed the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetic medications in 2010 due the concern of possible increased cardiovascular risk. It required healthcare providers to obtain a special certification in order to prescribe rosiglitazone and patients receiving rosiglitazone must be enrolled in the REMS program. In 2013, the FDA lifted the restrictions for the prescribing and use of rosiglitazone based on the data from RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes) trial. The RECORD trial demonstrated no elevated cardiovascular risk. Recently, the FDA has lifted the entire REMS requirements for rosiglitazone-containing medications, which includes Avandia (rosiglitazone), Avandamet (rosiglitazone-metformin) and Avandaryl (rosiglitazone-glimepiride) on the basis of post-marketing data and the RECORD trial. However, most of these medications have either been removed from the market (Avandamet and Avandaryl) or are rarely used in patients (Avandia).

Basaglar

The FDA gave final approval in December 2015 to Basaglar (a copycat version of insulin glargine). Basaglar was not approved as a “biosimilar” product although it was demonstrated to be similar enough to another insulin glargine on the market (Lantus) regarding its effectiveness and safety. It is administered subcutaneously with the manufacturer’s KwikPen injector once daily at any time of the day. Being as the first “follow-on” insulin glargine product, Basaglar received much attention for potentially lower costs. Basaglar has already launched in the UK under the brand name of Abasaglar and is priced 15% lower than Lantus (listed price of £35.28 for Abasaglar and £41.50 for Lantus according to UK Medicines Information). Pricing for Basaglar in the US is unknown at this time and the drug will not be available until after December this year.

 

References

1. FDA. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm Accessed on January 10, 2016.

2. FDA. Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication - FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm477601.htm Accessed on December 28, 2015.

3. FDA. FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm Accessed on December 28, 2015. 




02/11/2016

New Medicare Drug Spending Dashboard Published

Esther Liu, PharmD, MSIA, CGP

The Center for Medicare and Medicaid Services (CMS) released a new online dashboard that contains some interesting analyses of Medicare Part D drug utilization. The new dashboard presents drug data collected from Medicare Part B and Part D providers from 2010 to 2014.  In an analysis of the top 15 drugs by total annual cost for Medicare Part D 2014, 10 out of the top 15 high cost medications are drugs that commonly show up on newly admitted hospice patients’ medication profiles. The remaining 5 medications are all specialty medications used for chemotherapy, immunotherapy or hepatitis C treatment. These 5 medications are curative in nature and are not typically encountered by hospice providers.

The 10 high cost drugs identified by the analysis are Nexium, Crestor, Abilify, Advair, Spiriva, Lantus, Januvia, Duloxetine, Lyrica, and Namenda.  

Outcome Resources also targets these medications for our hospice providers in patient medication reviews and monthly drug utilization reviews. Many of these can be switched to a more cost-effective alternative or safely discontinued at the end of life. Below are the common recommendations provided by Outcome Resources clinicians to manage hospice patients who are on the drugs listed above:

 

  • Nexium is a proton pump inhibitor (PPI) which has recently become generic in early 2015. The generic version, esomeprazole, is also available over-the-counter at a much lower cost than the branded version. Omeprazole is another cost-effective alternative in the same class of PPIs that has been generically available for a long time.

  • Crestor is a statin for hyperlipidemia. There was a study done that supports the discontinuation of statins at the end of life. It has also been shown that the discontinuation of statins can improve the quality of life for terminal patients. The following is the link to the abstract of the study <http://abstracts.asco.org/144/AbstView_144_135132.html>.

  • Abilify is a branded atypical antipsychotic. It is not recommended to switch an antipsychotic if the patient has been stable on this medication to treat certain existing mental/mooddisorders (such as schizophrenia or bipolar disorder)However, if the patient was newly prescribed Abilify for terminal agitation, haloperidol would be the most cost-effective alternative in the hospice setting.

  • Advair and Spiriva are both inhaled respiratory medications. If patients have a terminal lung conditions, they often fail to have enough positive force to inhale medication contents from these handheld devices. These medications are often switched to the nebulized formulation for better efficacy when patients have significant lung dysfunction.

  • Lantus and Januvia are used for diabetes management. Tight blood glucose control only provides long term survival benefit, so it is no longer recommended in terminal patients. The risks of hypoglycemia and the potential side effects from the diabetes medication at end of life often outweigh the benefit, thus they should be considered for discontinuation for terminal patients.

  • Duloxetine and Lyrica are both commonly used for treating neuropathic pain. The cost effective alternative for these is gabapentin. Methadone is also a very cost effective option to manage neuropathic pain and other types of pain, particularly in patients who also require routine narcotics for pain or dyspnea.

  • Namenda is used to improve memory, awareness, and the ability to perform daily functions in Alzheimer’s patients. It has NOT been demonstrated to provide any benefit in end stage dementia (FAST level 7 or greater).   The potential adverse effects of Namenda, such as GI disturbance, are likely to outweigh any potential beneficial effects, so it is often recommended to discontinue these medications for patient with end stage Alzheimer’s disease.

If you are interested to learn more about the Medicare Drug Spending Dashboard 2014, the direct link is: <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Dashboard/Medicare-Drug-Spending/Drug_Spending_Dashboard.html>

 

More information:
https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Dashboard/Medicare-Drug-Spending/Drug_Spending_Dashboard.html


12/11/2015

Combination use of Proton Pump Inhibitors and H2 blockers - Is this appropriate?

Jennifer Chen, PharmD

Proton pump inhibitors (PPIs) and histamine H2 antagonists (H2 blockers) are the most common medications prescribed for the treatment of gastroesophageal reflux disease (GERD) or peptic ulcer disease (PUD). The treatment usually begins with antacids or over-the-counter H2 blockers for mild symptoms. Then steps up to PPIs or higher dose of H2 blockers for moderate to severe symptoms. Occasionally, PPI and H2 blocker may be combined to treat certain patients. This article will discuss the appropriateness of combination therapy and its associated risk.

Hospice patients are predisposed to PUD due to many risk factors including the age-related change in gastric mucosal defense, serious illness and long-term use of NSAID. The majority of patients are managed clinically with a once daily dose of a PPI. The unofficial use of twice daily dosing of PPI or the addition of a nighttime H2 blocker to the daytime PPI therapy may be required for optimal control in a subset of patients such as those with Barrett’s esophagus or extra-esophageal disease (1).

PPIs and H2 blockers have overlapping mechanisms of actions, which ultimately suppress gastric acid secretion, but at different stages of production. When used together, the extensive acid suppression therapy may decrease the absorption of certain nutrients (i.e. vitamin B12, iron and calcium), which are dependent upon an acidic environment to be absorbed in the stomach. There is also a significant risk of hip fractures with long-term PPI treatment. This risk theoretically may be further increased with the combination therapy due to impaired calcium absorption. Combination therapy may also increase the risk of gastrointestinal infections. A recent meta-analysis evaluated Clostridium difficle (C.diff) infections in patients receiving PPIs and found an association between PPI use and an increased risk of C diff (2). H2 blockers have been showed to carry a lower risk for gastrointestinal infection compared to PPIs. However, when both PPIs and H2 blockers are used together, the further reduction of gastric acid may allow for bacteria to multiply in the digestive system and the risk of infection may be increased.

In general, long-term combination therapy does not offer any additional benefit for the management of GERD and may only be appropriate in a particular subset of patients (i.e. Barrett’s esophagus or extra-esophageal disease). Practitioners are encouraged to re-evaluate patient’s condition and consider discontinuation if patient no longer exhibits symptoms or has no indication for continued use. Since PPIs provide superior acid suppression, healing rates and symptom relief compared to H2 blockers, our recommendation is to discontinue H2 blockers over PPIs. If it is determined PPI is no longer indicated for a patient, it should be tapered to avoid rebound acid reflux. For patients who require long-term PPI therapy, the lowest effective dose should be considered.

  1. Katz PO, Tutuian R. Histamine Receptor Antagonists, Proton Pump Inhibitors and their combination in the treatment of gastroesophageal reflux disease. Best Pract & Res Clin Gastroenterol 2001;15(3):371-84.
  2. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. The American journal of gastroenterology 2012 Jul;107(7):1011–9. 

 

 




11/11/2015

Hospice Medication Alert: Drug Safety Update on Entacapone

Jennifer Chen, PharmD

Entacapone is a reversible and selective inhibitor of catechol-O-methyltransferase (COMT). By disrupting levodopa breakdown, the COMT inhibitors can potentiate the effect of levodopa for managing the motor symptoms of Parkinson’s disease. Therefore, entacapone is used as adjunctive treatments in patients who are experiencing “wearing off” or other motor complications during treatment with carbidopa-levodopa.) It is available alone as Comtan® or in a fixed-dose combination with carbidopa-levodopa as Stalevo®.

In August 2010, FDA alerted patients and health care professionals about the increased risk of cardiovascular events and death with the use of Stalevo. The possible safety issue was observed in a clinical trial called Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s disease (STRIDE-PD) and in meta-analysis involving 15 clinical trials comparing Stalevo with carbidopa-levodopa. Since carbidopa-levodopa has been used extensively and has not been associated with cardiovascular risk, the FDA was concerned that entacapone might have been responsible for the increased risk. It was difficult to draw conclusions from these clinical trials because they were not designed to evaluate entacapone’s cardiovascular safety.

Until recently, two studies were examined to understand the significance of cardiovascular risk with entacapone. One was a retrospective cohort study using data from an electronic commercial insurance database and found the risk for myocardial infarction was not significantly increased in patients 18 to 64 years old with Parkinson’s disease treated with entacapone compared to the control group(1). The other study assessed the risk of myocardial infarction, stroke or death in Medicare patients at least 65 years old with Parkinson’s disease and the result did not support an associate between entacapone use and increased cardiovascular risks(2).

Therefore, on October 26, 2015, the FDA announced that entacapone does not carry an increased risk of cardiovascular events based on recent studies. However, patients and health care professionals are still encouraged to report side effects with Comtan or Stalevo to the FDA.

References

  1. Final Study Report, “The risk of incident myocardial infarction in Parkinson’s disease patients with add-on entacapone to levodopa/DDCI compared to other add-on Parkinson’s disease therapy without entacapone”. A retrospective cohort study using data from MarketScanTM; February 2014.
  2. Graham DJ, Williams JR, Hsueh YH, Calia K, Levenson M, Pinheiro SP, MaCurdy TE, Shih D, Worrall C, Kelman JA. Cardiovascular and mortality risks in Parkinson’s disease patients treated with entacapone. Mov Disord 2013;28:490-497.

 




First 10 <<Previous 10 Next 10 >> Last 10

 

 


Education Resources and Support for Hospices

Stay up-to-date on the latest hospice pharmacy benefits management information and tools with a variety of education resources and support at no extra charge. We offer presentations live at your facility, over the Internet or viaEducational Resources and Support for Hospicesteleconference, online service education programs, customized courses, and courses accredited for nursing continuing education credit.

See all of our educational resources>>

Clinical hospice and palliative cae consultation

Clinical Services

Our palliative care experts provide clinical consulting on important medication management and care decisions. Our non-dispensing pharmacists provide focused attention and unbiased advice.

 

Read more about our clinical pharmacy benefits management services>>

Why Use A PBM?

Contracting with multiple pharmacies, doing all the reporting, trying to stay current with medical practices and stay compliant while keeping costs down? There’s an easier and more effective way.

Find out how using a pharmacy benefits manager (PBM) can help you>>

Why Use a PBM